[1587] The Utility of LEF-1 Immunohistochemical Stain in the Diagnosis of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Douglas W Warden, Sarah Ondrejka, Lisa Durkin, Juraj Bodo, Eric D Hsi. Cleveland Clinic, Cleveland, OH
Background: Overexpression of lymphoid-enhancer-binding factor 1 (LEF-1) has recently been shown in virtually all cases of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) but not in other small B-cell lymphomas, opening the door for its use as an adjunct in the diagnosis of CLL/SLL. The feasibility and utility of LEF-1 immunohistochemical staining as a tool for the diagnosis of small B-cell lymphomas in decalcified bone marrow biopsy specimens has not been delineated.
Design: We performed immunohistochemical staining with a rabbit monoclonal LEF-1 antibody (Epitomics, Burlingame, CA, clone EPR2029Y) in 78 bone marrow and 56 lymph node/tissue samples of various small B-cell leukemias/lymphomas. An automated immunostainer (Leica BondMax) and heat induced epitope retrieval was used. Cases were considered positive if >70% of B-cells demonstrated nuclear immunoreactivity. CD3 and CD20 stains were simultaneously evaluated in order to assist with LEF-1 interpretation when significant T-cell infiltrates were also present.
Results: LEF-1 expression was observed in all 30 cases of CLL/SLL. Among the 104 non-CLL small B-cell lymphoma cases, only one (a CD5-negative lymphoplasmacytic lymphoma) expressed LEF-1. One case of splenic marginal zone lymphoma was not scored due to a significant T-cell infiltrate, which precluded confident interpretation. The remaining cases were negative (see table below). In our hands, LEF-1 showed a sensitivity and specificity for CLL/SLL of 100% and 99%.
| Diagnosis (N) | Bone Marrow | Lymph Node/ Tissue | ||
|---|---|---|---|---|
| LEF-1: | Positive | Negative | Positive | Negative |
| CLL/SLL (30) | 12 | 0 | 18 | 0 |
| Atypical CLL (2) | 0 | 2 | 0 | 0 |
| Follicular Lymphoma (17) | 0 | 7 | 0 | 10 |
| Hairy Cell Leukemia [HCL] (16) | 0 | 16 | 0 | 0 |
| HCL variant (2) | 0 | 2 | 0 | 0 |
| Lymphoplasmacytic lymphoma (22) | 1 | 10 | 0 | 11 |
| Mantle Cell Lymphoma (14) | 0 | 9 | 0 | 5 |
| Marginal zone lymphoma (20)* | 0 | 9 | 0 | 10 |
| B-cell lymphoproliferative disorder, nos (11) | 0 | 10 | 0 | 1 |